Inmune Bio, Inc. financial data

Symbol
INMB on Nasdaq
Location
225 Ne Mizner Blvd, Suite 640, Boca Raton, FL
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2025 - May 8, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 261 % -1.55%
Debt-to-equity 33 % -28.4%
Return On Equity -46.3 %
Return On Assets -89.4 % -53%
Operating Margin -26.2K % -152%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 22.9M shares +27.2%
Common Stock, Shares, Outstanding 22.9M shares +27.7%
Entity Public Float 135M USD +27.4%
Common Stock, Value, Issued 23K USD +27.8%
Weighted Average Number of Shares Outstanding, Basic 22.5M shares +24.8%
Weighted Average Number of Shares Outstanding, Diluted 22.5M shares +24.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 50K USD +257%
Research and Development Expense 32.1M USD +29.3%
General and Administrative Expense 9.46M USD -1.79%
Operating Income (Loss) -41.5M USD -20.9%
Nonoperating Income (Expense) 193K USD
Net Income (Loss) Attributable to Parent -40.8M USD -18.3%
Earnings Per Share, Basic -2 USD/shares -0.52%
Earnings Per Share, Diluted -2 USD/shares -0.52%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 19.3M USD -25.6%
Accounts Receivable, after Allowance for Credit Loss, Current 1.28M USD
Assets, Current 21M USD -29.7%
Operating Lease, Right-of-Use Asset 278K USD -28.5%
Intangible Assets, Net (Excluding Goodwill) 16.5M USD 0%
Other Assets, Noncurrent 49K USD -53.8%
Assets 37.8M USD -19.3%
Liabilities, Current 7.93M USD -54.6%
Operating Lease, Liability, Noncurrent 201K USD -44.2%
Liabilities 8.13M USD -54.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -610K USD +8.82%
Retained Earnings (Accumulated Deficit) -173M USD -30.9%
Stockholders' Equity Attributable to Parent 29.7M USD +5.13%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 50.7M USD -27.6%
Liabilities and Equity 37.8M USD -19.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.82M USD +8.72%
Net Cash Provided by (Used in) Financing Activities 5.27M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 22.9M shares +27.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.59M USD +83.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 19.3M USD -25.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 302K USD -32.9%
Deferred Tax Assets, Valuation Allowance 25.7M USD +31%
Deferred Tax Assets, Gross 25.7M USD +31.1%
Operating Lease, Liability 347K USD -28.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -40.7M USD -18.2%
Lessee, Operating Lease, Liability, to be Paid 393K USD -32.4%
Operating Lease, Liability, Current 146K USD +16.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 51K USD -74.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 198K USD +3.13%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 46K USD -52.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 51K USD -74.2%
Deferred Tax Assets, Operating Loss Carryforwards 8.69M USD +26.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 51K USD
Additional Paid in Capital 203M USD +26.2%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 545K USD
Share-based Payment Arrangement, Expense 2.08M USD
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%